Natixis Advisors, L.P. Genmab A/S Transaction History

Natixis Advisors, L.P.

$54.1 Billion
Q1 2025

A detailed history of Natixis Advisors, L.P. transactions in Genmab A/S stock. As of the latest transaction made, Natixis Advisors, L.P. holds 128,525 shares of GMAB stock, worth $2.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

128,525

Previous 205,769 37.54%

Holding current value

$2.8 Million

Previous $4.29 Million 41.41%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	SELL	$18.69 - $24.14 $1.44 Million - $1.86 Million	-77,244 Reduced 37.54%	128,525 $2.52 Million
Q4 2024 Feb 10, 2025	SELL	$20.02 - $24.15 $15,895 - $19,175	-794 Reduced 0.38%	205,769 $4.29 Million
Q3 2024 Nov 06, 2024	BUY	$23.84 - $28.48 $1.13 Million - $1.35 Million	47,437 Added 29.81%	206,563 $5.04 Million
Q2 2024 Aug 01, 2024	SELL	$25.13 - $30.27 $1.93 Million - $2.33 Million	-76,848 Reduced 32.57%	159,126 $4 Million
Q1 2024 Apr 25, 2024	BUY	$26.43 - $32.77 $1.27 Million - $1.58 Million	48,176 Added 25.65%	235,974 $7.06 Million
Q4 2023 Feb 06, 2024	SELL	$27.94 - $35.44 $1.15 Million - $1.46 Million	-41,099 Reduced 17.96%	187,798 $5.98 Million
Q3 2023 Nov 13, 2023	BUY	$35.27 - $42.24 $2.26 Million - $2.71 Million	64,085 Added 38.88%	228,897 $8.07 Million
Q2 2023 Aug 15, 2023	SELL	$37.4 - $42.94 $470,679 - $540,399	-12,585 Reduced 7.09%	164,812 $6.27 Million
Q1 2023 May 11, 2023	SELL	$34.88 - $43.22 $799,100 - $990,170	-22,910 Reduced 11.44%	177,397 $6.7 Million
Q4 2022 Jan 27, 2023	SELL	$33.8 - $47.06 $1.25 Million - $1.74 Million	-36,907 Reduced 15.56%	200,307 $8.49 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $3.44 Million - $40.8 Million	109,103 Added 85.16%	237,214 $7.62 Million
Q2 2022 Aug 12, 2022	SELL	$26.83 - $38.57 $680,703 - $978,559	-25,371 Reduced 16.53%	128,111 $4.16 Million
Q1 2022 May 12, 2022	BUY	$30.95 - $39.68 $272,669 - $349,580	8,810 Added 6.09%	153,482 $5.55 Million
Q4 2021 Feb 08, 2022	SELL	$35.87 - $47.12 $2,331 - $3,062	-65 Reduced 0.04%	144,672 $5.72 Million
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $630,355 - $739,131	-15,171 Reduced 9.49%	144,737 $6.33 Million
Q2 2021 Aug 12, 2021	BUY	$32.88 - $44.57 $1.12 Million - $1.52 Million	34,095 Added 27.1%	159,908 $6.53 Million
Q1 2021 May 05, 2021	SELL	$30.92 - $44.4 $274,878 - $394,716	-8,890 Reduced 6.6%	125,813 $4.13 Million
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $70,686 - $85,596	2,100 Added 1.58%	134,703 $5.48 Million
Q3 2020 Nov 12, 2020	SELL	$33.07 - $38.68 $862,267 - $1.01 Million	-26,074 Reduced 16.43%	132,603 $4.86 Million
Q2 2020 Aug 11, 2020	SELL	$20.05 - $33.89 $3.6 Million - $6.09 Million	-179,779 Reduced 53.12%	158,677 $5.38 Million
Q1 2020 Apr 27, 2020	BUY	$17.15 - $25.22 $912,808 - $1.34 Million	53,225 Added 18.66%	338,456 $7.17 Million
Q4 2019 Feb 10, 2020	BUY	$18.88 - $24.14 $118,944 - $152,082	6,300 Added 2.26%	285,231 $6.37 Million
Q3 2019 Nov 12, 2019	BUY	$18.0 - $21.38 $5.02 Million - $5.96 Million	278,931 New	278,931 $5.65 Million

Others Institutions Holding GMAB

# of Institutions

248

Shares Held

66.2M

Call Options Held

729K

Put Options Held

398K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.4B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Genmab A/S Transaction History